These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 9469350

  • 21. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study.
    Bisagni G, Boni C, Manenti AL, Moretti G, Rondini E, Sassi M, Zadro A, Savoldi L.
    Tumori; 1998; 84(6):659-61. PubMed ID: 10080671
    [Abstract] [Full Text] [Related]

  • 22. Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
    Pronzato P, Vigani A, Pensa F, Vanoli M, Tani F, Vaira F.
    Am J Clin Oncol; 1997 Oct; 20(5):519-21. PubMed ID: 9345341
    [Abstract] [Full Text] [Related]

  • 23. Use of mesna to prevent ifosfamide-induced urotoxicity.
    Siu LL, Moore MJ.
    Support Care Cancer; 1998 Mar; 6(2):144-54. PubMed ID: 9540174
    [Abstract] [Full Text] [Related]

  • 24. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C, Küpfer A, Schefer H, Cerny T.
    Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
    Lind MJ, Margison JM, Cerny T, Thatcher N, Wilkinson PM.
    Cancer Res; 1989 Feb 01; 49(3):753-7. PubMed ID: 2910494
    [Abstract] [Full Text] [Related]

  • 28. Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Foxall PJ, Singer JM, Hartley JM, Neild GH, Lapsley M, Nicholson JK, Souhami RL.
    Clin Cancer Res; 1997 Sep 01; 3(9):1507-18. PubMed ID: 9815837
    [Abstract] [Full Text] [Related]

  • 29. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 30. Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
    Sutton G, Blessing JA, Park R, DiSaia PJ, Rosenshein N.
    Obstet Gynecol; 1996 May 01; 87(5 Pt 1):747-50. PubMed ID: 8677079
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Smith PF, Booker BM, Creaven P, Perez R, Pendyala L.
    J Clin Pharmacol; 2003 Dec 01; 43(12):1324-8. PubMed ID: 14615468
    [Abstract] [Full Text] [Related]

  • 32. Ifosfamide in non-small cell lung cancer.
    Johnson DH.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):7-10. PubMed ID: 8677453
    [Abstract] [Full Text] [Related]

  • 33. Oral mesna: a review.
    Goren MP.
    Semin Oncol; 1992 Dec 01; 19(6 Suppl 12):65-71. PubMed ID: 1485175
    [Abstract] [Full Text] [Related]

  • 34. Ifosfamide in the treatment of soft tissue sarcomas.
    Connelly EF, Budd GT.
    Semin Oncol; 1996 Jun 01; 23(3 Suppl 6):16-21. PubMed ID: 8677442
    [Abstract] [Full Text] [Related]

  • 35. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
    Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, Lentz SS, Sorosky J, Hsiu JG.
    Gynecol Oncol; 2000 Nov 01; 79(2):147-53. PubMed ID: 11063636
    [Abstract] [Full Text] [Related]

  • 36. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis.
    Lima MV, Ferreira FV, Macedo FY, de Castro Brito GA, Ribeiro RA.
    Cancer Chemother Pharmacol; 2007 Apr 01; 59(5):643-50. PubMed ID: 16947012
    [Abstract] [Full Text] [Related]

  • 37. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
    Coriat R, Mir O, Camps S, Ropert S, Billemont B, Leconte M, Larousserie F, Anract P, Alexandre J, Goldwasser F.
    Cancer Chemother Pharmacol; 2010 Feb 01; 65(3):491-5. PubMed ID: 19588140
    [Abstract] [Full Text] [Related]

  • 38. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B, Pamir A, Buyukcelik A, Utkan G, Akbulut H, Demirkazik A, Icli F.
    Exp Oncol; 2004 Dec 01; 26(4):320-5. PubMed ID: 15627067
    [Abstract] [Full Text] [Related]

  • 39. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna.
    Fleming RA, Cruz JM, Webb CD, Kucera GL, Perry JJ, Hurd DD.
    Bone Marrow Transplant; 1996 Apr 01; 17(4):497-501. PubMed ID: 8722345
    [Abstract] [Full Text] [Related]

  • 40. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
    Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey MF, Brunner KW, Küpfer A.
    J Cancer Res Clin Oncol; 1991 Apr 01; 117 Suppl 4():S135-8. PubMed ID: 1795002
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.